Ketorolac and patient controlled analgesia in the treatment of postoperative pain

P. A. Cataldo, A. J. Senagore, M. J. Kilbride

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Ketorolac tromethamine (Toradol® [Syntex, Palo Alto]), a new commercially available nonsteroidal anti-inflammatory drug (NSAID), has appropriate solubility and minimal tissue irritation, making it suitable for intramuscular injection. Previously, NSAID have only been available for oral use in the United States for the treatment of pain. Ketorolac, the most potent NSAID known, relieves pain through inhibition of arachidonic acid synthesis at the cyclooxygenase level and has no central opioid effects. The results of previous studies using parenteral ketorolac in combination with patient administered narcotics have shown a 40 percent reduction in narcotic requirements. However, ketorolac is presently only approved for intramuscular injection and oral use in the United States. In a prospective, randomized study, we compared intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (morphine) (PCA-M) to PCA-M alone for the control of pain after extensive colonic resections. The combination of intramuscular ketorolac and PCA-M provided equal pain relief with no increased side effects when compared with narcotics alone. However, narcotic requirements of the patients were decreased by an average of 45 percent. Ketorolac and narcotics in combination provide effective postoperative pain relief and significantly decrease narcotic requirements. This combination may be particularly beneficial in the subpopulation of patients especially prone to narcotic related complications.

Original languageEnglish (US)
Pages (from-to)435-438
Number of pages4
JournalSurgery Gynecology and Obstetrics
Volume176
Issue number5
StatePublished - 1993
Externally publishedYes

Fingerprint

Ketorolac
Patient-Controlled Analgesia
Narcotics
Postoperative Pain
Passive Cutaneous Anaphylaxis
Ketorolac Tromethamine
Pain
Anti-Inflammatory Agents
Intramuscular Injections
Therapeutics
Pharmaceutical Preparations
Prostaglandin-Endoperoxide Synthases
Arachidonic Acid
Solubility
Analgesia
Morphine
Opioid Analgesics
Prospective Studies

ASJC Scopus subject areas

  • Obstetrics and Gynecology
  • Surgery

Cite this

Cataldo, P. A., Senagore, A. J., & Kilbride, M. J. (1993). Ketorolac and patient controlled analgesia in the treatment of postoperative pain. Surgery Gynecology and Obstetrics, 176(5), 435-438.

Ketorolac and patient controlled analgesia in the treatment of postoperative pain. / Cataldo, P. A.; Senagore, A. J.; Kilbride, M. J.

In: Surgery Gynecology and Obstetrics, Vol. 176, No. 5, 1993, p. 435-438.

Research output: Contribution to journalArticle

Cataldo, PA, Senagore, AJ & Kilbride, MJ 1993, 'Ketorolac and patient controlled analgesia in the treatment of postoperative pain', Surgery Gynecology and Obstetrics, vol. 176, no. 5, pp. 435-438.
Cataldo, P. A. ; Senagore, A. J. ; Kilbride, M. J. / Ketorolac and patient controlled analgesia in the treatment of postoperative pain. In: Surgery Gynecology and Obstetrics. 1993 ; Vol. 176, No. 5. pp. 435-438.
@article{122cbdd0dcd04a5cb784ab72ba23ce3a,
title = "Ketorolac and patient controlled analgesia in the treatment of postoperative pain",
abstract = "Ketorolac tromethamine (Toradol{\circledR} [Syntex, Palo Alto]), a new commercially available nonsteroidal anti-inflammatory drug (NSAID), has appropriate solubility and minimal tissue irritation, making it suitable for intramuscular injection. Previously, NSAID have only been available for oral use in the United States for the treatment of pain. Ketorolac, the most potent NSAID known, relieves pain through inhibition of arachidonic acid synthesis at the cyclooxygenase level and has no central opioid effects. The results of previous studies using parenteral ketorolac in combination with patient administered narcotics have shown a 40 percent reduction in narcotic requirements. However, ketorolac is presently only approved for intramuscular injection and oral use in the United States. In a prospective, randomized study, we compared intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (morphine) (PCA-M) to PCA-M alone for the control of pain after extensive colonic resections. The combination of intramuscular ketorolac and PCA-M provided equal pain relief with no increased side effects when compared with narcotics alone. However, narcotic requirements of the patients were decreased by an average of 45 percent. Ketorolac and narcotics in combination provide effective postoperative pain relief and significantly decrease narcotic requirements. This combination may be particularly beneficial in the subpopulation of patients especially prone to narcotic related complications.",
author = "Cataldo, {P. A.} and Senagore, {A. J.} and Kilbride, {M. J.}",
year = "1993",
language = "English (US)",
volume = "176",
pages = "435--438",
journal = "Journal of the American College of Surgeons",
issn = "1072-7515",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Ketorolac and patient controlled analgesia in the treatment of postoperative pain

AU - Cataldo, P. A.

AU - Senagore, A. J.

AU - Kilbride, M. J.

PY - 1993

Y1 - 1993

N2 - Ketorolac tromethamine (Toradol® [Syntex, Palo Alto]), a new commercially available nonsteroidal anti-inflammatory drug (NSAID), has appropriate solubility and minimal tissue irritation, making it suitable for intramuscular injection. Previously, NSAID have only been available for oral use in the United States for the treatment of pain. Ketorolac, the most potent NSAID known, relieves pain through inhibition of arachidonic acid synthesis at the cyclooxygenase level and has no central opioid effects. The results of previous studies using parenteral ketorolac in combination with patient administered narcotics have shown a 40 percent reduction in narcotic requirements. However, ketorolac is presently only approved for intramuscular injection and oral use in the United States. In a prospective, randomized study, we compared intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (morphine) (PCA-M) to PCA-M alone for the control of pain after extensive colonic resections. The combination of intramuscular ketorolac and PCA-M provided equal pain relief with no increased side effects when compared with narcotics alone. However, narcotic requirements of the patients were decreased by an average of 45 percent. Ketorolac and narcotics in combination provide effective postoperative pain relief and significantly decrease narcotic requirements. This combination may be particularly beneficial in the subpopulation of patients especially prone to narcotic related complications.

AB - Ketorolac tromethamine (Toradol® [Syntex, Palo Alto]), a new commercially available nonsteroidal anti-inflammatory drug (NSAID), has appropriate solubility and minimal tissue irritation, making it suitable for intramuscular injection. Previously, NSAID have only been available for oral use in the United States for the treatment of pain. Ketorolac, the most potent NSAID known, relieves pain through inhibition of arachidonic acid synthesis at the cyclooxygenase level and has no central opioid effects. The results of previous studies using parenteral ketorolac in combination with patient administered narcotics have shown a 40 percent reduction in narcotic requirements. However, ketorolac is presently only approved for intramuscular injection and oral use in the United States. In a prospective, randomized study, we compared intramuscular ketorolac in combination with patient controlled intravenous narcotic analgesia (morphine) (PCA-M) to PCA-M alone for the control of pain after extensive colonic resections. The combination of intramuscular ketorolac and PCA-M provided equal pain relief with no increased side effects when compared with narcotics alone. However, narcotic requirements of the patients were decreased by an average of 45 percent. Ketorolac and narcotics in combination provide effective postoperative pain relief and significantly decrease narcotic requirements. This combination may be particularly beneficial in the subpopulation of patients especially prone to narcotic related complications.

UR - http://www.scopus.com/inward/record.url?scp=0027159315&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027159315&partnerID=8YFLogxK

M3 - Article

C2 - 8480264

AN - SCOPUS:0027159315

VL - 176

SP - 435

EP - 438

JO - Journal of the American College of Surgeons

JF - Journal of the American College of Surgeons

SN - 1072-7515

IS - 5

ER -